Symbol="YMAB"
AssetType="Common Stock"
Name="Y mAbs Therapeutics"
Description="Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of new antibody-based therapeutics for the treatment of cancer in the United States. The company is headquartered in New York, New York."
CIK="1722964"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="750 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="281285000"
EBITDA="-57817000"
PERatio="None"
PEGRatio="None"
BookValue="2.469"
DividendPerShare="0"
DividendYield="0"
EPS="-1.56"
RevenuePerShareTTM="1.717"
ProfitMargin="-0.985"
OperatingMarginTTM="-0.782"
ReturnOnAssetsTTM="-0.223"
ReturnOnEquityTTM="-0.557"
RevenueTTM="75032000"
GrossProfitTTM="57700000"
DilutedEPSTTM="-1.56"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.931"
AnalystTargetPrice="12.71"
TrailingPE="-"
ForwardPE="119.05"
PriceToSalesRatioTTM="5.21"
PriceToBookRatio="2.056"
EVToRevenue="2.523"
EVToEBITDA="-0.852"
Beta="0.693"
num_52WeekHigh="20.48"
num_52WeekLow="2.7"
num_50DayMovingAverage="7.87"
num_200DayMovingAverage="6.65"
SharesOutstanding="43677800"
DividendDate="None"
ExDividendDate="None"
symbol="YMAB"
open="6.25"
high="6.64"
low="6.18"
price="6.44"
volume="285996.00"
latest_trading_day="2023-07-07"
previous_close="6.22"
change="0.22"
change_percent="3.5370%"
aroon_positive_momentum_days="73"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="73"
Volume_recent_avg="576780"
Change_recent_avg="-0.01"
Delta_recent_avg="0.51"
Variance_recent_avg="0.25"
Change_ratio_recent_avg="-0.26"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="73"
Aroon_momentum_negative="27"
image_negative_thumbnail_id_1="1124"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0157.jpeg"
image_negative_thumbnail_id_2="1129"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0162.jpeg"
image_neutral_thumbnail_id_1="583"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_neutral_thumbnail_id_2="581"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0018.jpeg"
image_positive_thumbnail_id_1="1015"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0177.jpeg"
image_positive_thumbnail_id_2="636"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0072.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1168"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
